Neurocrine Biosciences, Inc.San Diego, California, United States
Disclosure information not submitted.
SAT-459 - A Modified Delphi Panel of US Endocrinologists to Align on Minimum Clinically Important Difference (MCID) in Glucocorticoid Dose and Other Key Uncertainties in Classic Congenital Adrenal Hyperplasia (CAH)
Saturday, June 13, 20269:30 AM - 4:30 PM CT
SUN-458 - Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the Cahtalyst™ Adult Study
Sunday, June 14, 20269:00 AM - 4:00 PM CT
SUN-467 - A Cross-Sectional Survey on Crinecerfont and Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia (CAH) in the United States (US) Participating in Cahtalyst Adult Open-Label Extension (OLE) Study
SUN-468 - Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in Cahtalyst™ Adult Study
ORF32-02 - Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog™ Registry
Sunday, June 14, 20261:50 PM - 1:55 PM CT
ORF32-07 - Crinecerfont Improves Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst™ Adult Study
Sunday, June 14, 20262:55 PM - 3:10 PM CT
MON-495 - Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog™ Registry
Monday, June 15, 20269:00 AM - 2:00 PM CT
.jpg)
.jpg)